Grupo Vita and H-Pharm Corporation conclude licensing agreement for an antihypertensive drug
Eneas, an antihypertensive drug developed by the Spanish pharmaceutical group Vita, will be marketed in Korea by H-Pharm Co. Eneas, the first combination for the treatment of hypertension developed by a Spanish pharmaceutical company, was approved and launched into the Spanish market in June 2002.
Eneas, an antihypertensive drug developed by the Spanish pharmaceutical group Vita, will be marketed in Korea by H-Pharm Co. Eneas, the first combination for the treatment of hypertension developed by a Spanish pharmaceutical company, was approved and launched into the Spanish market in June 2002.
It is a fixed-dose combination of an ACE-inhibitor, enalapril, and a calcium antagonist, nitrendipine. It is intended for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled with monotherapy.
'Now one of Grupo Vita's priorities is to keep on concluding strategic alliances to introduce our own research and development pharmaceutical products into international markets,' said managing director Jose Luis Malagarriga.
The company says that Eneas fits very well into the H-Pharm Co. portfolio of drugs in the Korean market as it follows the trend towards greater use of combinations for their superior efficacy and safety compared with monotherapy. The forecast sales in Korea are put at about 200,000 units in five years and the company expects to reach a market share of 30%.